首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   927884篇
  免费   67559篇
  国内免费   1335篇
耳鼻咽喉   12952篇
儿科学   24330篇
妇产科学   23228篇
基础医学   132511篇
口腔科学   28224篇
临床医学   80194篇
内科学   182300篇
皮肤病学   19217篇
神经病学   72041篇
特种医学   36770篇
外国民族医学   79篇
外科学   151877篇
综合类   18010篇
现状与发展   1篇
一般理论   234篇
预防医学   61428篇
眼科学   21268篇
药学   72468篇
  3篇
中国医学   2146篇
肿瘤学   57497篇
  2018年   8962篇
  2017年   7026篇
  2016年   7759篇
  2015年   8857篇
  2014年   11982篇
  2013年   17496篇
  2012年   24077篇
  2011年   25025篇
  2010年   14797篇
  2009年   14263篇
  2008年   24602篇
  2007年   25690篇
  2006年   26481篇
  2005年   25426篇
  2004年   24560篇
  2003年   23607篇
  2002年   23154篇
  2001年   54725篇
  2000年   56544篇
  1999年   46949篇
  1998年   10731篇
  1997年   9434篇
  1996年   9127篇
  1995年   8876篇
  1994年   8248篇
  1993年   7568篇
  1992年   35454篇
  1991年   33908篇
  1990年   32723篇
  1989年   31856篇
  1988年   28971篇
  1987年   28240篇
  1986年   26274篇
  1985年   25137篇
  1984年   17814篇
  1983年   15117篇
  1982年   7763篇
  1981年   6736篇
  1979年   15756篇
  1978年   10581篇
  1977年   9025篇
  1976年   7859篇
  1975年   8616篇
  1974年   10453篇
  1973年   9849篇
  1972年   9354篇
  1971年   8847篇
  1970年   8414篇
  1969年   7916篇
  1968年   7197篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
52.
53.
54.
Background Immune checkpoint blockers (ICBs) activate CD8+ T cells, eliciting both anti-cancer activity and immune-related adverse events (irAEs). The relationship of irAEs with baseline parameters and clinical outcome is unclear.Methods Retrospective evaluation of irAEs on survival was performed across primary (N = 144) and secondary (N = 211) independent cohorts of patients with metastatic melanoma receiving single agent (pembrolizumab/nivolumab—sICB) or combination (nivolumab and ipilimumab—cICB) checkpoint blockade. RNA from pre-treatment and post-treatment CD8+ T cells was sequenced and differential gene expression according to irAE development assessed.Results 58.3% of patients developed early irAEs and this was associated with longer progression-free (PFS) and overall survival (OS) across both cohorts (log-rank test, OS: P < 0.0001). Median survival for patients without irAEs was 16.6 months (95% CI: 10.9–33.4) versus not-reached (P = 2.8 × 10−6). Pre-treatment monocyte and neutrophil counts, but not BMI, were additional predictors of clinical outcome. Differential expression of numerous gene pathway members was observed in CD8+ T cells according to irAE development, and patients not developing irAEs demonstrating upregulated CXCR1 pre- and post-treatment.Conclusions Early irAE development post-ICB is associated with favourable survival in MM. Development of irAEs is coupled to expression of numerous gene pathways, suggesting irAE development in-part reflects baseline immune activation.Subject terms: Immunotherapy, Melanoma  相似文献   
55.
Monatsschrift Kinderheilkunde - Bedürfnisse onkologisch erkrankter Kinder im Kontext der Versorgung sind noch wenig erforscht, was u.?a. in einem Mangel an entsprechenden...  相似文献   
56.
57.
58.
59.
Journal of Thrombosis and Thrombolysis - Amniotic fluid embolism (AFE) is a catastrophic condition in the peripartum period and still remains as a leading cause of maternal death. Although over 80%...  相似文献   
60.
PurposeOur purpose was to determine the effect of chemoradiotherapy (CRT) on patient-reported quality of life (QOL) for patients with intact pancreas cancer.Methods and MaterialsWe reviewed a prospective QOL registry for patients with intact, clinically localized pancreatic ductal adenocarcinoma treated with CRT between June 2015 and November 2018. QOL was assessed pre-CRT (immediately before CRT, after neoadjuvant chemotherapy) and at the completion of CRT with the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) and its component parts: FACT-General (FACT-G) and hepatobiliary cancer subscore (HCS). A minimally important difference from pre-CRT was defined as ≥ 6, 5, and 8 points for FACT-G, HCS, and FACT-Hep, respectively.ResultsOf 157 patients who underwent CRT, 100 completed both pre- and post-CRT surveys and were included in the primary analysis. Median age at diagnosis was 65 years (range, 23-90). National Comprehensive Cancer Network resectability status was resectable (3%), borderline resectable (40%), or locally advanced (57%). Folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) (75%) or gemcitabine and nab-paclitaxel (42%) were given for a median of 6 cycles (range, 0-42) before CRT. Radiation therapy techniques included 3-dimensional conformal (22%), intensity modulated photon (55%), and intensity modulated proton (23%) radiation therapy to a median dose of 50 Gy (range, 36-62.5). Concurrent chemotherapy was most commonly capecitabine (82%). Sixty-three patients (63%) had surgery after CRT. The mean decline in FACT-G, HCS subscale, and FACT-Hep from pre- to post-CRT was 3.5 (standard deviation [SD], 13.7), 1.7 (SD 7.8), and 5.2 (SD 19.4), respectively. Each of these changes were statistically significant, but did not meet the minimally important difference threshold. Pancreatic head tumor location was associated with decline in FACT-Hep. Nausea was the toxicity with the greatest increase from pre- to post-CRT by both physician-assessment and patient-reported QOL.ConclusionsFor patients with intact pancreatic adenocarcinoma, modern CRT is well tolerated with minimal decline in QOL during treatment.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号